Charles River Laboratories International, Inc. (NYSE:CRL) Position Lowered by Amalgamated Bank

Amalgamated Bank lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 22.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,121 shares of the medical research company's stock after selling 2,915 shares during the period. Amalgamated Bank's holdings in Charles River Laboratories International were worth $1,994,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Tortoise Investment Management LLC lifted its position in shares of Charles River Laboratories International by 77.0% during the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company's stock valued at $27,000 after buying an additional 57 shares in the last quarter. Wolff Wiese Magana LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $32,000. Headlands Technologies LLC bought a new stake in shares of Charles River Laboratories International in the 1st quarter worth about $41,000. Whittier Trust Co. of Nevada Inc. grew its holdings in Charles River Laboratories International by 219.3% during the 2nd quarter. Whittier Trust Co. of Nevada Inc. now owns 281 shares of the medical research company's stock worth $58,000 after acquiring an additional 193 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Charles River Laboratories International during the 3rd quarter worth about $79,000. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 2.8 %

Shares of CRL traded down $6.09 during mid-day trading on Tuesday, reaching $214.60. The company's stock had a trading volume of 453,834 shares, compared to its average volume of 615,974. The company's fifty day moving average price is $194.37 and its two-hundred day moving average price is $208.00. Charles River Laboratories International, Inc. has a 52 week low of $168.24 and a 52 week high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.21 and a debt-to-equity ratio of 0.61. The stock has a market cap of $10.97 billion, a PE ratio of 27.62, a P/E/G ratio of 5.80 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $975.99 million. During the same quarter last year, the business earned $2.72 EPS. The firm's revenue was down 1.6% compared to the same quarter last year. On average, analysts predict that Charles River Laboratories International, Inc. will post 10.2 earnings per share for the current fiscal year.

Charles River Laboratories International declared that its board has approved a share repurchase program on Wednesday, August 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's management believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CRL shares. Bank of America cut Charles River Laboratories International from a "buy" rating to a "neutral" rating and cut their price target for the stock from $250.00 to $215.00 in a report on Wednesday, October 2nd. JPMorgan Chase & Co. lowered Charles River Laboratories International from an "overweight" rating to a "neutral" rating and decreased their target price for the company from $270.00 to $205.00 in a research report on Thursday, August 8th. The Goldman Sachs Group cut their target price on Charles River Laboratories International from $290.00 to $250.00 and set a "buy" rating for the company in a research note on Thursday, August 8th. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a research report on Thursday, November 7th. Finally, CLSA upgraded Charles River Laboratories International from an "underperform" rating to a "hold" rating and set a $205.00 price target for the company in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International currently has a consensus rating of "Hold" and a consensus price target of $217.54.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).